Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amsterdam Molecular Therapeutics (AMT) said that the European Union has awarded EUR3.3m grant to the Aipgene consortium, of which AMT is a member, to develop gene therapy product for acute intermittent porphyria (AIP).
Subscribe to our email newsletter
AMT holds the commercialization rights to the AIP gene therapy (AMT-021).
Under this grant, AMT expects to obtain EUR1.1m, which will cover almost 75% of AMT’s overall development cost of the product to complete Phase I/II study in humans.
With the support of the all the Aipgene partners, AMT anticipates AIP patient enrollment in a clinical trial to begin in 2012.
AMT CEO Jorn Aldag said this grant allows them to prioritize the development of our AIP gene therapy program for this progressive and devastating disease within AMT’s pipeline, as well as initiating the next step in advancing a potentially more effective, long-term treatment for patients.